673 related articles for article (PubMed ID: 19143643)
21. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
22. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.
Ehninger D
Neuropharmacology; 2013 May; 68():97-105. PubMed ID: 22626986
[TBL] [Abstract][Full Text] [Related]
23. A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis.
Noonan DJ; Lou D; Griffith N; Vanaman TC
Arch Biochem Biophys; 2002 Feb; 398(1):132-40. PubMed ID: 11811958
[TBL] [Abstract][Full Text] [Related]
24. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis.
Waltereit R; Welzl H; Dichgans J; Lipp HP; Schmidt WJ; Weller M
J Neurochem; 2006 Jan; 96(2):407-13. PubMed ID: 16300636
[TBL] [Abstract][Full Text] [Related]
25. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis.
Bonnet CS; Aldred M; von Ruhland C; Harris R; Sandford R; Cheadle JP
Hum Mol Genet; 2009 Jun; 18(12):2166-76. PubMed ID: 19321600
[TBL] [Abstract][Full Text] [Related]
26. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
28. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
Jozwiak J; Jozwiak S; Oldak M
Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
[TBL] [Abstract][Full Text] [Related]
29. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
30. The mTOR pathway and its role in human genetic diseases.
Rosner M; Hanneder M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Mutat Res; 2008; 659(3):284-92. PubMed ID: 18598780
[TBL] [Abstract][Full Text] [Related]
31. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
[TBL] [Abstract][Full Text] [Related]
33. Management of epilepsy in tuberous sclerosis complex.
Curatolo P; D'Argenzio L; Cerminara C; Bombardieri R
Expert Rev Neurother; 2008 Mar; 8(3):457-67. PubMed ID: 18345974
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
[TBL] [Abstract][Full Text] [Related]
35. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway.
Jiang X; Yeung RS
Cancer Res; 2006 May; 66(10):5258-69. PubMed ID: 16707451
[TBL] [Abstract][Full Text] [Related]
36. Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.
Moavero R; Romagnoli G; Graziola F; Curatolo P
Semin Pediatr Neurol; 2015 Dec; 22(4):282-94. PubMed ID: 26706015
[TBL] [Abstract][Full Text] [Related]
37. The tuberous sclerosis complex and its highly variable manifestations.
Lendvay TS; Marshall FF
J Urol; 2003 May; 169(5):1635-42. PubMed ID: 12686801
[TBL] [Abstract][Full Text] [Related]
38. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
39. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
